SpaceX has exercised the option to acquire @cursor_ai in an all-stock transaction with the goal of building the world’s most useful AI models.
For the past few months, SpaceXAI has been jointly training a model with Cursor, which will be released in Cursor and Grok Build soon.
We look forward to working closely with the Cursor team to advance our frontier AI capabilities
Hungarian PM Magyar shreds the homophobes and defends gay parents.
NatCons claim to defend Western values. They have it backwards.
Western values ARE constitutional rule of law and a government that stays out of your bedroom.
Magyar represents the only future for the right.
📢 ASUS ExpertCenter Pro ET900N G3 is now available to order worldwide.
Built on @nvidia GB300 Grace Blackwell Ultra Desktop Superchip:
🧠 748GB coherent memory
🤖 1 trillion parameter models
⚡ Data-center-class performance
Learn more: https://t.co/NnNmZAamHf
#NVIDIA#AI
This is a super exciting release - Claude Fable 5 is the same underlying model as Mythos but with added safeguards. The benchmarks are great and it's SOTA on everything by a margin but I'll add that *qualitatively* also, this is a major-version-bump-deserving step change forward (imo of the same order as Claude 4.5 was in November), peaking especially for long problem-solving sessions on very difficult problems. You can give it a lot more ambitious tasks than what you're used to, the model "gets it" and it will just go, and it's never felt this tempting to stop looking at the code at all (but don't do this in prod!). The model still has quirks that people will run into and the safeguards are configured to be a little too trigger happy for launch, which can hopefully be tuned over time.
I feel a lot of things changing as working software increasingly comes out on a tap. The Jevon's paradox kicks in and I feel my own demand for software growing substantially. You can ask for anything - explainers, visualizers, dashboards, bespoke single-use apps (e.g. a full wandb that is hyper-specific just for your project), you can 10X your test suite, auto-optimize code, run giant research projects with custom HTML for the results, anything! "Free your mind" (Matrix ref). Really looking forward to all the things people build!
Introducing Claude Fable 5: a Mythos-class model that we’ve made safe for general use.
Its capabilities exceed those of any model we’ve ever made generally available.
A new, experimental medication nearly doubled overall survival rates for patients with advanced pancreatic cancer, according to the results of a study published Sunday.
https://t.co/8d4D416b6v
Our internal data shows Claude is accelerating AI development—a possible path to recursive self-improvement, or AI autonomously building a more capable successor.
It’s happening faster than we thought, and the implications deserve greater attention. https://t.co/OVVPJO7VQx
هذا العالم غريب كل يوم يصدمنا بشي أغرب
تخيلوا يا اخوان هذي ورقة علمية برروا فيها علماء "فلسفيًا" بأنه لا مانع أخلاقي من تطوير القراد جينيًا عشان يصيب البشر بمتلازمة ألفا-غال مما يجعل لدينا حساسية من اللحوم ونتوقف عن قتل الحيوانات، فنتطور اخلاقيا
تذكرت زيك بهجوم العمالقة
Terence Tao: AI is creating a “traffic jam” in math
If AI generates more proofs than humans can verify, science needs new infrastructure. SAIR competitions build that infrastructure by surfacing high-quality results, so the best work is not lost in a flood of AI-generated math.
A former doctoral student has shaken China’s academic establishment by accusing prominent scholars of fabricating data and manipulating papers, triggering investigations at several leading institutions and drawing attention from state media.
@YuxuanJia02
https://t.co/eQzktuIsEb
Eli Lilly has done it.
They've gone and made what seems to be a powerful, permanent gene therapy for LDL cholesterol.
That means they'll be able to effectively prevent most heart disease with a single infusion!
الحمدلله … اليوم تم اطلاق موقعي https://t.co/HM0CKhcerk
واللي باذن الله يكون احد اسباب تسهيل وصول ملفات المرضى الى الدكاترة حول العالم.
فكرة الموقع باختصار:
ارفع كل ملفاتك الطبية من اشعة وتحاليل وادوية وتقارير وتشخيصات وسجل صوت لحالتك وانشرها برابط واحد فيه ككلللل شي.
الموقع فيه كثير من المميزات الثانية مثل انه تقدر تسال الAI عن حالتك وتقاريرك وغيرها كثير…
السبب اللي خلاني اسوي الموقع:
تعب الوالد ومرضه ودخوله مستشفيات كثير وتغيير واطباء كثير فكثرت ملفاته الطبية وحالته تعقدت فكثير نصحوني اسافر برا للعلاج..
ولكن ما كان عندي القدرة للسفر ولا كنت اقدر ارسل ملفات الوالد وتقاريره واشعته للدكاترة بالخارج…
فمع الموقع هذا قدرت ارسلهم رابط واحد فيه كل شي مهم وكل التحاليل اللي يطلبوها الخ، بالاضافة الى انه اقدر اعمل معاه اتصال فيديو من نفس الموقع.
مثال لرابط حالة:
https://t.co/BV6QmcyJ4F
بناء عليها قضيت على ظاهرة "لازم اسافر للعلاج"
الحين تقدر تأخذ رأي أي طبيب خارجي بدون ما تسافر، وترسله كل شيء بلينك واحد.
من عنده تجربة مع الملفات الطبية والاستشارات الخارجية؟
وش أكبر صعوبة تواجهونها في إرسال التقارير للأطباء برا؟
لو حابين فيديو شرح لل��وقع قولوا لي 👇
Eli Lilly just released Phase 3 data for retatrutide, their next-generation obesity drug. 2,339 patients. 80 weeks. The biggest trial in the field.
8 things worth knowing:
1️⃣ It beats every obesity drug on the market. Wegovy (semaglutide): 15% Zepbound (tirzepatide): 22% Retatrutide: 25%
2️⃣ You don’t need the highest dose. The lowest (4mg) already outperforms Wegovy. 18% weight loss with one dose increase. Fewer people quit than on the sugar pill.
3️⃣ At two years, weight was still dropping. No plateau. Patients with BMI over 35 lost 84 pounds. 30% of their body weight.
4️⃣ Some patients stopped taking it because they lost too much weight. That’s never happened with an obesity drug.
5️⃣ It works differently. Ozempic and Zepbound suppress appetite. Retatrutide does that too, but its third receptor (glucagon) flips your metabolism toward burning stored fat. In Phase 2, ketone bodies rose 2-3x, confirming the body was switching fuel sources.
6️⃣ It causes a side effect no other obesity drug does: tingling and numbness (12.5%). New receptor, new trade-off. Worth watching.
7️⃣ In a separate study, it cleared 86% of liver fat. 93% of patients reached normal levels. 1 in 3 adults have fatty liver disease. No approved drug comes close.
8️⃣ Two-thirds of patients on the highest dose were reclassified out of obesity entirely. They started at BMI 40. They finished under 30. That’s not just weight loss. That’s a medical reclassification.
@US_FDA filing expected late 2026.
Today, we share a breakthrough on the planar unit distance problem, a famous open question first posed by Paul Erdős in 1946.
For nearly 80 years, mathematicians believed the best possible solutions looked roughly like square grids.
An OpenAI model has now disproved that belief, discovering an entirely new family of constructions that performs better.
This marks the first time AI has autonomously solved a prominent open problem central to a field of mathematics.